



(12) **EUROPEAN PATENT APPLICATION**

(21) Application number : **92303533.1**

(51) Int. Cl.⁵ : **C12N 15/55, C12N 9/14,
A23K 1/17, A23L 3/3571,
A61K 37/54, C12Q 1/04**

(22) Date of filing : **21.04.92**

The microorganism(s) has (have) been
deposited with NCTC under numbers 12452,
12453 and with NCIMB under number 40400.

(30) Priority : **20.04.91 GB 9108498**

(43) Date of publication of application :
28.10.92 Bulletin 92/44

(84) Designated Contracting States :
**AT BE CH DE DK ES FR GB GR IT LI LU MC NL
PT SE**

(71) Applicant : **AGRICULTURAL AND FOOD
RESEARCH COUNCIL
Norwich Research Park
Colney, Norwich NR4 7UA (GB)**

(72) Inventor : **Gasson, Michael John
Old Ash Farm, Stone Lane, Bintree
Dereham, Norfolk NR20 5NA (GB)**

(74) Representative : **Bassett, Richard Simon et al
ERIC POTTER & CLARKSON St. Mary's Court
St. Mary's Gate
Nottingham NG1 1LE (GB)**

(54) **Bacteriophage lysins and their applications in destroying and testing for bacteria.**

(57) Bacteriophages of food-contaminating or pathogenic bacteria or the lysins thereof are used to kill such bacteria. Examples include lysins from bacteriophages of *Listeria monocytogenes* and *Clostridium tyrobutyricum*.

Tests for bacterial contamination can be made specific for specific bacteria by using the appropriate bacteriophage or lysin thereof and determining whether cells are lysed thereby.

EP 0 510 90

This invention relates to the use of bacterial viruses (bacteriophages) which use bacteria as hosts and produce a bacteriophage lysin responsible for cell-wall degradation and lysis of the host cells.

Attempts to use a bacteriophage as an antimicrobial agent have failed to be effective. We have previously used the lysin of the bacteriophage ϕ ML3 of *Lactococcus lactis* ML3, which is active against all strains of all subspecies of *Lactococcus lactis*, very weakly affects group D enterococci, but does not have any action on a wide variety of other species tested (Shearman *et al* (1989) *Molecular and General Genetics* 218: 214-221), to lyse cheese starter cultures (WO90/00599). WO/00599 also discloses the use of micro-organisms, transformed to express the ϕ ML3 lysin, to suppress populations of bacteria susceptible to the lysin, ie the *Lactococcus lactis* cheese starter culture strains.

It is also known to use cheese starter culture bacteria to produce the simple peptide nisin in order to destroy harmful bacteria.

We have now found that further bacteriophage lysins can be used to destroy unwanted bacteria, especially food-contaminating bacteria prejudicial to health.

A first aspect of the present invention provides a formulation comprising a lysin of a bacteriophage of a food-contaminating or pathogenic bacterium or a variant of such a lysin, substantially free of the bacteriophage.

Preferably the *Listeria* phage ϕ LM4 or *Clostridium tyrobutyricum* phage ϕ P lysins are used. They act against all tested species and strains of *Listeria* and also strains of *Kurthia zopfii*, or against *Clostridium tyrobutyricum* (as appropriate), but lack activity against other tested species.

A "variant" of such a lysin is any polypeptide of which at least 30% (preferably at least 50%, 75%, 90%, 95% or 99%) has at least 80% (preferably at least 90%, 95% or 99%) amino acid homology with the corresponding region of the lysin itself and which has at least 30% (preferably at least 50%, 75%, 90% or 95%) of the bacterial lysing capability of the said lysin.

Food-contaminating bacteria are those which, by virtue of their presence or compounds produced by them, cause undesirable flavours, odours or visual appearances or cause illness in humans or animals consuming the food.

The organism which is destroyed may be any of the following:

Listeria monocytogenes, *Clostridium tyrobutyricum*, *Clostridium botulinum*, *Clostridium perfringens*, lactic acid bacteria (eg *Lactobacillus brevis*) causing beer spoilage, *Salmonella spp.*, *Yersinia spp.*, *Campylobacter*, *E. coli*, *Pseudomonas spp.*, *Staphylococcus*, *Bacillus spp.* (including *Bacillus cereus*), *Shigella spp.* and *Vibrio spp.*

Pathogenic bacteria include all pathogenic bacteria of humans, animals and plants. However, in a medical or veterinary context, as is explained further below, bacteria involved in topical or superficial infections are of particular interest. These include *Staphylococcus spp.* (eg *Staph. aureus*), *Streptococcus spp.*, *Corynebacterium spp.*, *Clostridium spp.* (eg *Cl. perfringens*), *Yersinia spp.* (eg *Y. pestis*), *Pasteurella spp.* (eg *P. multocida*), *Streptobacillus spp.* (eg *Streptobacillus moniliformis*), *Proteus spp.* (eg *P. mirabilis*) and *Pseudomonas spp.*

A second aspect of the invention provides a substantially pure preparation of a lysin from a bacteriophage of a food-contaminating or pathogenic bacterium.

A third aspect of the invention provides a coding sequence for such a lysin.

A fourth aspect provides a DNA construct comprising a coding sequence as above in an expression vehicle suitable for transformation of a microbial host or cell line.

Suitable regulatory expression vectors, transformation techniques, and hosts are all known in the art. The host may be any micro-organism or cell line which is found to express the said lysin gene, and may be a bacterium such as *E. coli* or *Lactococcus lactis*, a yeast such as *Saccharomyces cerevisiae* or *Kluyveromyces lactis* or a filamentous fungus such as *Aspergillus niger*.

Thus a fifth aspect provides a microbial or cell line host transformed with such an expression vehicle and capable of expressing the lysin coding sequence.

A sixth aspect provides a polypeptide derived from the expression of the said lysin coding sequence in a suitable host transformed with such an expression vehicle.

A seventh aspect of the present invention provides a method of destroying pathogenic or food-contaminating bacteria characterised in that said bacteria are lysed with a lysin or a variant of such a lysin from a bacteriophage of such bacteria.

The use of such a preparation in food or agriculture simply involves the addition of an amount sufficient to provide an inhibitory concentration of lysin activity. The specific activity of any preparation may readily be calculated, for example by use of the spectrophotometric assay described later. The quantity of preparation necessary for effective protection in a given food may be arrived at by routine experimentation. The lysin is applied in a suitable, non-toxic aqueous medium. Any food may be treated with such a preparation by addition or application to surfaces eg of cut, cooked meat or poultry, soft cheeses and pâtés of fish or meat. The term "food" includes drinks (such as water, beer, milk and soft drinks), animal food (such as pet food or cattle food) and

produce destined for consumption by humans or animals (such as stored potatoes). In agriculture, a particular application is addition to silage where *Listeria* and *Clostridium tyrobutyricum* are known to present a problem that can be passed on up the food chain. In brewing, brewing yeast transformed with a lysin gene may be used.

In a medical or veterinary context, because the lysin is likely to be degraded or to produce an immune reaction, it is preferred to administer it topically in diseases of the skin such as ulcers, burns and acne. It may be applied as the clinician directs, as a lotion, cream or ointment.

An eighth aspect provides a method of testing for the presence of bacteria which are lysed by a bacteriophage or by the lysin thereof, comprising exposing a sample to the said bacteriophage or lysin and determining whether bacteria have been lysed as a result of such exposure.

Any technology that exploits the release of intracellular biochemicals (eg ATP or enzymes such as alkaline phosphatase or esterase) to detect micro-organisms can, in accordance with the invention, be made specific for the target range of such lysins. For example, an ATP or phosphatase release test for *Listeria* using the *Listeria* bacteriophage or lysin thereof, in which the release of ATP or phosphatase is detected (eg by linkage to a luciferase reaction and monitoring of photon release or by spectrophotometric methods as is described below) indicates the specific presence of *Listeria* in a sample. The invention further provides a kit comprising a lysin and means to detect bacterial lysis.

Preferably, the bacteriophage in all these contexts is or at least includes *Listeria monocytogenes* øLM4 or a bacteriophage of *Clostridium tyrobutyricum*, such as øP1. Several different lysins may be used in order to destroy or identify a specific range of bacteria.

The cloning and characterization of the gene for the lysin of the *Listeria* bacteriophage øLM4 has facilitated the production of the free lysin and the availability of its structural gene. These components have application in the protection of environment and food material from pathogenic strains of *Listeria*. The free lysin acts as a novel antimicrobial that kills such bacteria and the gene can be genetically engineered in a non-pathogenic micro-organism such that the latter produce the *Listeria* lysin thereby equipping it with a novel anti-*Listeria* capability. For example, a food-grade micro-organism may be transformed with a DNA construct comprising a coding sequence for the lysin.

Preferred embodiments of the invention will now be described by way of example with reference to the accompanying drawings, in which:-

Figure 1 shows patches of *E. coli* clones with *Hind*III fragments of øLM4 DNA in the *Hind*III site of vector pUC18. The plate is overlayed with a suspension of *Listeria monocytogenes* 6868 cells and lysin producing clones create clear zones around the patch (indicated by an arrow).

Figure 2 is a restriction and deletion map of lysin-expressing clone pF1322. The result of lysin activity tests is indicated to the right. The inferred location of the lysin gene is shown. Arrows indicate the orientation of the lysin gene with respect to the *lac* α promoter of the pUC vector used which is transcribed from left to right in this figure (ie pF1324 is opposed to the *lac* α promoter, other clones are transcribed in the same direction as the *lac* α promoter).

Plasmid pF1322 is pUC18 carrying a 3.6kb *Hind*III fragment of bacteriophage øLM4 DNA. Plasmid pF1326 is pF1322 with a 0.56kb *Hind*III - *Sa*I deletion. Plasmid pF1327 is pF1322 with a 1.32kb *Hind*III - *Eco*RI deletion. Plasmid pF1324 is pUC18 carrying a 1.9kb *Hind*III - *Nru*I fragment of pF1322 cloned between its *Hind*III and *Hinc*II sites. Plasmid pF1325 is pUC18 carrying a 1.6kb *Nru*I - *Hind*III fragment of pF1322 cloned between its *Hinc*II and *Hind*III sites. Plasmid pF1328 is pUC19 carrying a 1.9kb *Hind*III - *Nru*I fragment of pF1322 cloned between its *Hind*III and *Hinc*II sites. Plasmid pF1329 is pF1328 carrying a 1.6kb *Ba*I deletion from the polylinker *Bam*HI site. Plasmid pF1330 is pF1328 carrying a 1.6kb *Ba*I deletion from the polylinker *Bam*HI site.

Figure 3 illustrates the response of a suspension of *Listeria monocytogenes* 6868 cells to cell free extracts of *E. coli* strains harbouring plasmids pF1322(▲), pF1328(Δ), pF1329(○) and pUC19(●).

Figure 4 is a Coomassie blue stained SDS polyacrylamide gel of proteins produced by *E. coli* strain carrying the T7 expression vector pSP73 (tracks 2 and 3) or pF1331 which carries the lysin gene (tracks 4 and 5). Un-induced cells (tracks 2 and 4) are compared with induced cells (tracks 3 and 5). Molecular weight markers are present (tracks 1 and 6) and the expressed lysin protein is indicated by an arrow.

Figure 5 illustrates the sequencing strategy used. The extent and direction of sequencing is indicated by the arrows. The arrow shows the direction of transcription of the lysin gene.

Figure 6 shows a single strand of the region of øLM4 DNA that encodes the lysin gene.

Figure 7 is the Analyseq print out of the analysis of the DNA sequence shown in Figure 6. The identification of the open reading frame of the lysin gene is in the top panel.

Figure 8 shows the double stranded DNA sequence of the lysin structural gene and its translated protein product.

Figure 9 shows the protective effect of cloned *Listeria* lysin on skimmed milk to which *Listeria Monocytogenes* is added.

Figure 10 shows the expression of the *Listeria* lysin gene in *Lactococcus lactis* under the control of the lactose inducible lactococcal lactose operon promoter.

EXAMPLE 1: CLONING OF LYSIN GENE, ETC

Isolation of bacteriophage ϕ LM4

A bacteriophage named ϕ LM4 was isolated from a culture of *Listeria monocytogenes* serotype 4b that was originally obtained from a listeriosis outbreak in Nova Scotia, Canada in 1981. The source of the infection was tracked down to contaminated coleslaw. This culture of *Listeria monocytogenes* was deposited under the Budapest Treaty as NCTC 12452 in the National Collection of Type Cultures, Central Public Health Laboratory, Colindale, London, UK on 21 March 1991. The bacteriophage was purified by standard single plaque isolation procedure using *Listeria monocytogenes* F6868 as the host. This culture was similarly deposited under the Budapest Treaty as NCTC 12453 in the National Collection of Type Cultures, Central Public Health Laboratory, Colindale, London, UK on 21 March 1991. Examination of this bacteriophage by electron microscopy revealed it to have an isometric head with a diameter of approximately 50nm and a tail of approximately 250nm.

Isolation of DNA from *Listeria monocytogenes* bacteriophage ϕ LM4

20ml of an 18 hour culture of *Listeria monocytogenes* F6868 was inoculated into 500ml of Bacto tryptose phosphate broth and incubated with shaking at 30°C. When O.D. 600 reached 0.15 the culture was infected with 5×10^{10} p.f.u. of bacteriophage ϕ LM4 and incubated until lysis was apparent as a loss of turbidity. The lysate was centrifuged at 6000 x g for 10 min at 4°C. The bacteriophage lysate was then concentrated by polyethylene glycol precipitation and purified on caesium chloride stepped gradients using well established protocols (Bachrach and Friedmann (1971) *Applied Microbiology* 22: 706-715). Bacteriophage DNA was extracted by dialysis against 50% formamide in TE buffer (0.1 Tris - HCl, 0.01M EDTA, pH 8.5). Further purification was then performed on caesium chloride-ethidium bromide equilibrium density gradients. Examination of the bacteriophage DNA by agarose gel electrophoresis revealed the genome to be approximately 39kb in size.

Cloning the bacteriophage ϕ LM4 lysin gene

DNA purified from bacteriophage ϕ LM4 was digested with restriction endonuclease *Hind*III and ligated to plasmid pUC18 vector DNA that had also been cleaved with restriction endonuclease *Hind*III. The ligated DNA was transformed into *Escherichia coli* TB1 and ampicillin resistant colonies were selected on LB agar containing 50µg/ml ampicillin, 40µg/ml isopropyl-β-D-thiogalactopyranoside (IPTG) and 40µg/ml 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-gal). These steps were performed using well established protocols (Sambrook, J. *et al* (1989), *Molecular Cloning. A laboratory manual*. Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 2nd Edition).

White colonies were screened for their ability to produce a bacteriophage lysin active against *Listeria monocytogenes*. These colonies were patched onto duplicate Bacto tryptose agar plates and incubated for 18 hours at 37°C. One plate was exposed to chloroform vapour for 10 min and then seeded with 0.2ml of an 18 hour broth culture of *Listeria monocytogenes* F6868. After incubation at 30°C for 18 hours clear zones of lysins were apparent around patches of clones expressing the *Listeria* bacteriophage ϕ LM4 lysin. This is illustrated in Figure 1. Positive clones were recovered from the duplicate plate and the pUC18 derivative plasmid isolated and characterized by digestion with restriction endonuclease *Hind*III. One lysin expressing pUC18 clone that contained a 3.6kb insert of ϕ LM4 DNA was chosen for further analysis. This plasmid was designated pFI322.

Deletion analysis of lysin expressing plasmid pFI322

Characterization of pFI322 was undertaken by constructing a restriction map of this insert using single and double digests with a variety of restriction enzymes. The map is presented in Figure 2. Deletion of some regions of the 3.6kb insert contained in pFI322 was achieved by digestion with certain of these enzymes, religation and transformation into *E. coli* TB1. In other instances endonuclease *Bal* 31 was used to introduce deletions. In addition, some regions of the 3.6kb cloned DNA in pFI322 were deleted by digestion with certain restriction endonucleases and re-cloning into appropriately cleaved plasmid vectors pUC18 or pUC19 and transformation into *E. coli* TB1. These manipulations are clearly documented in Figure 2 which is presented in the form of a deletion map for pFI322. After confirming that the various constructed plasmids derived from pFI322 had the expected structures, these clones were tested for their ability to produce *Listeria* bacteriophage lysin. As well

as the plate assay described above and illustrated in Figure 1, a spectrophotometric assay was also used. For this the *E. coli* strain carrying plasmid clones were grown at 37°C for 18 hours, harvested by centrifugation at 6000 x g for 5 min at 4°C, washed down once in 100mM Tris buffer pH7.5 and resuspended in this same buffer at approximately 10mg dry weight/ml. Cell free extracts were made by 6 cycles of ultrasonication (15 sec on, 10 sec off) at 0°C using the microprobe of an MSE Soniprep 150. Unbroken cells and cell debris were removed by centrifugation at 25000 x g for 15 min at 4°C.

Samples of the cell free extracts were added to an equilibrated (5 min at 37°C) 4ml reaction mixture containing 400µmole Tris HCl pH7.5 and *Listeria monocytogenes* F6868 indicator cells that had been harvested and resuspended at an O.D. 600 of 2.3. The fall in optical density caused by lysis of indicator cells was followed using a spectrophotometer. Typical results from use of this protocol are presented in Figure 3. The lytic activity of the plasmid derivative described above and in Figure 2 were assessed using both of these methods and the results are presented in Figure 2.

These results demonstrated that the structural gene for bacteriophage øLM4 was contained within the left hand 1.2kb of the DNA cloned in pFI322 and defined by the *Hind*III site at co-ordinate 0 and the *Eco*R1 site at co-ordinate 1.25 of the map illustrated in Figure 2.

Figure 2 also indicates the orientation of *Listeria* bacteriophage øLM4 DNA with respect to the *E. coli* *lac* α promoter that is present on vectors pUC18 and pUC19. It is apparent that a positive reaction in the lysin assay is only found when one orientation is maintained (eg pFI324 is negative whereas pFI328 is positive even though both constructs contain the same *Listeria* bacteriophage øLM4 fragment). This suggests that expression of the lysin gene depends on use of the *E. coli* *lac* α promoter and that no *Listeria* bacteriophage øLM4 promoter is present and active in *E. coli*.

Detection of the lysin protein

In order to identify a protein produced by the fragment of øLM4 DNA that expressed lysin activity another *E. coli* vector was used. A 2kb fragment from plasmid pFI328 between the *Hind*III site at co-ordinate 0 and a unique *Bam*HI site present on the polylinker of pUC19 was isolated and cloned between the *Hind*III and *Bam*HI sites of the T7 expression vector pSP73 that was purchased from Promega. The constructed plasmid named pFI331 was transformed into the *E. coli* host strain JM109DE3.

The *E. coli* T7 promoter in this vector is expressed by the phage specific T7 RNA polymerase which is induced by addition of IPTG in the appropriate host strain *E. coli* JM109 DE3. Cultures of this strain carrying pSP73 as a control or pFI331 were grown for 3 hours and induced by addition of 1PTG to a final concentration of 0.2mM. Incubation was continued for a further 3 hours before the cultures were harvested and used to prepare cell extracts using well-established, published procedures (Studier, F.W., Rosenberg, A.H., Dunn, J.J. and Dubendorff, J.W. (1990) *Methods in Enzymology* 185: 60-89).

Proteins present in cell extracts were analysed using conventional SDS-polyacrylamide gel electrophoresis (Laemmli (1970) *Nature* 227: 680-685). The results presented in Figure 4 clearly demonstrate that the 2kb fragment of pFI331 expresses a single protein with a molecular size of 31 kilodaltons which represents the lysin enzyme.

DNA sequence of the *Listeria* bacteriophage øLM4 lysin gene

The region of DNA between co-ordinate 0 and 1.2 in Figure 2 was subject to oligonucleotide sequence analysis using the dideoxy chain-termination method (Sanger, F., Coulson, A.R., Barrell, B.G., Smith, A.J.H. and Roe, B.A. (1980) *J. Molec. Biol.* 143) with a sequenase version 2.0 kit (United States Biochemical Corporation). The 0.9kb *Hind*III - *Eco*RI and the 0.3kb *Eco*RI - *Eco*RI fragments of pFI328 were subcloned in the M13 sequencing vectors M13mp18 and M13mp19 to create templates and sequenced using universal and synthetic oligonucleotide primers. To sequence across the internal *Eco*RI site at co-ordinate 0.9 double stranded sequencing of pFI329 plasmid DNA was used. The sequencing strategy is presented in Figure 5 and the complete DNA sequence is in Figure 6. The sequence was analysed using the computer program ANALYSEQ (Staden)

The protocol from the ANALYSEQ analysis is presented in Figure 7. The complete reading frame representing the lysin structural gene and its translated protein product is presented in Figure 8. The molecular size of the translated protein was calculated to be 32.9 kilodaltons which agrees well with the calculated 31 kilodalton size of the protein expressed by the T7 vector pSP73 (Clone pFI331 in Figure 4).

Activity and specificity of the *Listeria* bacteriophage ϕ LM4 lysin

Figure 3 illustrates the lytic activity of crude cell free extracts of *E. coli* TB1 carrying the plasmids pFI322, pFI328, pFI329 and pUC19 assayed using the spectrophotometric method described above. This activity was related to units of commercially available mutanolysin (Sigma) as has been described previously (Shearman, C., Underwood, H, Jury, K. and Gasson M. (1989) *Mol. Gen. Genetics* **218**: 214-221). The crude cell extracts of lysin expressing clones typically contained 5000 mutanolysin equivalent units per mg. protein.

In order to test the spectrum of activity of this lysin, the spectrophotometric assay was performed on 16 serotypes of *Listeria monocytogenes*, all other species of *Listeria*, the related species *Kurthia zopfii* and a variety of other gram positive and gram negative bacteria. The results compiled in Table 1 show that the *Listeria* bacteriophage ϕ LM4 lysin was active against all tested strains of *Listeria monocytogenes*, *Listeria innocua*, *Listeria ivanovii*, *Listeria murrayi*, *Listeria seelegri*, *Listeria welshimeri*, *Listeria grayi* and *Kurthia zopfii*. No activity was found against any of the other species tested.

TABLE 1: ACTIVITY OF CLONED LYSIN AGAINST LISTERIA SPECIES

5	Organism	Strain	Serotype	Relative ^a	Time (min) ^b
				Activity	$\Delta OD_{600}=1$
10	<i>Listeria monocytogenes</i>	F6868	4b	1.00	20
		NCTC 7973	1a	0.19	53
		NCTC 5412	4b	0.90	13
15		F4642	4b	0.92	14
		NCTC10357	1a	0.92	20
		BL87/41	4	0.66	25
20		NCTC 5348	2	0.10	78
		SLCC2373	3a	1.20	17
		SLCC2540	3b	0.19	60
25		SLCC2479	3c	0.15	60
		SLCC2374	4a	0.54	30
		SLCC2376	4c	0.19	90
30		SLCC2377	4d	0.08	90
		SLCC2378	4e	0.56	28
		SLCC2482	7	0.45	36
35		L3056	1/2a	0.49	30
		L4203	1/2a	0.36	41
40	Organism	Strain	Serotype	Relative ^a	Time (min) ^b
				Activity	$\Delta OD_{600}=1$
45		L4490	1/2b	0.29	55
		L1378	1/2b	0.09	150
		L4281	1/2c	0.11	120
50		L3304	1/2c	0.12	90
		L3253	4bx	0.66	26
		L2248	4bx	0.08	72
55	<i>Listeria ivanovii</i>	NCTC11288	6a	0.90	10
		NCTC11007		0.95	18

		SLCC5579	0.51	30
	<i>Listeria</i>	NCTC11856	1.10	15
5	<i>seeligeri</i>			
	<i>Listeria</i>	NCTC11857	0.29	36
	<i>welshimeri</i>			
	<i>Listeria</i>	NCTC10812	0.86	15
10	<i>murrayi</i>			
	<i>Listeria</i>	NCTC10815	0.93	12
	<i>grayi</i>			
15	<i>Kurthia</i>	NCTC10597	0.54	28
	<i>zopfii</i>			

Table 1 shows the relative sensitivity of a selection of strains of *Listeria* and *Kurthia zopfii* to the bacteriophage ϕ LM4 lysin. a) Relative activity is the fall in optical density (O.D.₆₀₀) from 2.3 achieved in 30 minutes divided by the equivalent fall obtained using *Listeria monocytogenes* F6868. b) The time (min) taken for a fall in optical density of O.D.₆₀₀ from 2.3 to 1.3 (O.D.₆₀₀ fall of 1) is recorded. Other strains tested which show no sensitivity to lysin were *Aeromonas hydrophila* NCTC 8049, *Bacillus cereus* NCTC 11143, *Brocothrix thermosphacta* NCTC 10822, *Carnobacterium piscicola* BL90/14, *Enterococcus faecalis* BL90/11, *Escherichia coli* BL90/12, *Klebsiella pneumoniae* NCFB 711, *Pseudomonas fluorescens* BL 78/45, *Staphylococcus aureus* NCTC 10652, *Streptococcus pneumoniae* NCTC 7465, *Streptococcus pyogenes* NCTC 2381.

In addition it was observed that the lysin was active at temperatures as low as 2°C. At 2°C addition of lysin to suspensions of *Listeria monocytogenes* caused a decrease of between 0.7 and 2.0 O.D.₆₀₀ units within 24 hours.

EXAMPLE 2: USE OF LYSIN TO CONTROL LISTERIA

Use as a free lysin

There are two distinct application concepts. One exploits a preparation of lysin enzyme manufactured by fermentation of a genetically engineered micro-organism that expresses the lysin gene product (Free lysin). The host organism may be *E. coli*, or any other bacterial species such as *Lactococcus lactis*, a yeast such as *Saccharomyces cerevisiae* or *Kluveromyces* lactis or a filamentous fungus such as *Aspergillus niger*. The lysin gene may be expressed intracellularly in which case a preparation may consist of a cell free lysate of the producing organism with some purification of the lysin, for example by ammonium sulphate precipitation and/or column chromatography. Alternatively the fermentation micro-organism may secrete lysin into the culture medium in which case the supernatant of the centrifuged fermentation broth provides the basis of a preparation, which again may require some purification.

The effectiveness of a crude extract of cloned *Listeria* lysin was demonstrated by its addition to skimmed milk containing *Listeria monocytogenes*. As illustrated in Fig. 9 the lysin preparation reduces the viable count of *Listeria monocytogenes* and after 22 days incubation at 8°C there is a viable count difference of 10⁸ *Listeria* cfu between milk containing lysin and the control sample.

Expression of Lysin by a genetically engineered micro-organism

An alternative application concept is to use a genetically engineered micro-organism that is compatible with a food or agricultural environment such as a species of lactic acid bacteria. Such an organism then grows in a food or agricultural environment and expresses an introduced gene for *Listeria* bacteriophage lysin. The gene may be expressed intracellularly and released into food or an agricultural environment by autolysis or induced lysis of that micro-organism. Alternatively the lysin may be secreted by a micro-organism so that active lysin is released into a food or agricultural environment by that viable micro-organism. In these cases the lysin gene is placed downstream of an appropriate promoter such as the lactose operon promoter or the proteinase promoter of *Lactococcus lactis* NCFB 712. Secretion may be achieved by fusion of the lysin structural gene to a

The ϕ LM-4 lysin gene together with the lacA promoter/lacR gene was cloned into pF145, a plasmid expressing the *Lactococcus* phage ϕ vML3 lysin gene which causes lysis during stationary phase of *L. lactis* cultures carrying the plasmid (Shearman et al (1992) *Biotechnology* 10: 196-199). The resulting plasmid pF1535 in *L. lactis* MG5267 when grown on lactose produced a culture that grew to stationary phase, then lysed as a consequence of the ϕ vML3 lysin, releasing ϕ LM-4 lysin into the culture supernatant.

25

The detection of lysis may be achieved by assaying an intracellular enzyme or metabolite. Especially useful enzyme assays are for phosphatase or for esterase. Alkaline phosphate can be assayed spectrophotometrically by following appearance of p-nitrophenol, which is yellow, from the colourless substrate p-nitrophenyl-phosphate at 405nm. Esterase activity can be assayed using fluorescein diacetate which is cleaved to acetate and fluorescent fluorescein and measuring the latter in a fluorometer. One especially suitable metabolite assay involves ATP detection. For this the well established luciferase assay in which ATP molecules generate light is exploited. Light emission may be measured in a luminometer. (An example of an end point detection reagent using luciferase-luciferin is marketed by Sigma Chemical Company as product L-1761).

45

9

Bacteriophage øP1 was deposited at the National Collections of Industrial and Marine Bacteria, 23 St Machar Drive, Aberdeen, AB2 1RY, Scotland on 5 April 1991 and a new deposit was made on 4 July 1991 under the Budapest Treaty and has been accorded Accession No NCIMB 40400.

5

Claims

1. A formulation comprising a lysin of a bacteriophage of a food-contaminating or pathogenic bacterium or a variant of such a lysin, substantially free of the bacteriophage itself.
- 10 2. A formulation according to Claim 1 wherein the bacteriophage is a *Listeria monocytogenes* bacteriophage.
3. A formulation according to Claim 2 wherein the bacteriophage is øLM4.
- 15 4. A formulation according to Claim 1 wherein the bacteriophage is a *Clostridium tyrobutyricum* bacteriophage.
5. A method of destroying micro-organisms characterised in that said micro-organisms are lysed with a formulation according to any one of the preceding claims.
- 20 6. A method according to Claim 5 wherein pathogenic strains of *Listeria* or *Clostridium* are destroyed in or on food products.
7. A substantially pure preparation of a *Listeria* or *Clostridium* bacteriophage lysin.
- 25 8. A nucleotide coding sequence for the lysin of a bacteriophage of a food-contaminating or pathogenic bacterium or a variant of such a lysin.
9. A coding sequence comprising the DNA coding sequence given in Figure 6 or a variant thereof encoding the same polypeptide.
- 30 10. An expression vehicle comprising a coding sequence according to Claim 8 or 9 and regulatory regions associated therewith for expression of the coding sequence in a suitable host.
11. A microbial host transformed with means to express a lysin of a bacteriophage of a pathogenic or food-contaminating bacterium or a variant of such a lysin.
- 35 12. A host according to Claim 11 which is a food-grade micro-organism.
13. A lysin derived from the cultivation of a host according to Claim 11.
- 40 14. A method of testing for specific bacteria in a sample, comprising adding a bacteriophage or bacteriophage lysin to the sample and determining whether bacterial cells have been lysed thereby.

45

50

55

EP 0 510 907 A2




FIG. 1




FIGURE 2




FIGURE 3




Fig. 4




FIGURE 5

1 AAGCTTTACT GGATAACGAC AAAC⁻TAGA⁻AC TGACAGATGA AGGACTGAAA
 51 GGCCTTGACG AACAGCTAGG AGCATTGCAA GAAAGCGATG CTTATTTGTT
 101 TGCTCAAGAA AGCGAGGCGG GCGGAACTG GTTTATTTGA ACAATTTACT
 151 AATCGAGCTA AAAAATATGG AAAGGATGAT TAATAATGGC ATTAACAGAG
 201 GCATGGCTAA TTGAAAAAGC AAATCGCAAA TTGAATACGT CAGGTATGAA
 251 TAAAGCTACA TCTGATAAGA CTCGGAATGT AATTA⁻AAAAA ATGGCAAAAG
 301 AAGGGATTTA TCTTTGTGTT GCGCAAGGTT ACCGCTCAAC AGCGGAACAA
 351 AATGCGCTAT ATGCACAAGG GAGAACCAAA CCTGGAGCGA TTGTTACTAA
 401 TGCTAAAGGT GGGCAATCTA ATCATAATTT CGGTGTAGCA GTTGATTTGT
 451 GCTTGTATAC GAGCGACGGA AAAGATGTTA TTTGGGAGTC GACAAC⁻TTC
 501 CGGTGGAAAA AGGTTGTTGC TGCTATGAAA GCGGAAGGAT TCGAATGGGG
 551 CGGAGATTGG AAAAGTTT⁻TA AAGACTATCC GCATTTTGA CTATGTGACG
 601 CTGTAAGTGG TGAGAAAATC CCTACTGCGA CACAAAACAC CAATCCAAAC
 651 AGACATGATG GGAAAATCGT TGACAGCGCG CCACTATTGC CAAAAATGGA
 701 CTTTAAATCA AATCCAGCGC GCATGTATAA ATCAGGAACT GAGTTCTTAG
 751 TATATGAACA TAATCAATAT TGGTACAAGA CGTACATCAA CGACAAATTA
 801 TACTACATGT ATAAGAGCTT TTGGGATGTT GTAGCTAAAA AAGATGCAAA
 851 AGGACGCATC AAAGTTGGA TTA⁻AAAGCGC GAAAGACTTA CGAATTCCAG
 901 TTTGGAATAA CACAAAATTG AATTCTGGGA AAATTAAATG GTATGCACCC
 951 AATACAAAAT TAGCATGGTA CAACAACGGA AAAGGATACT TGGA⁻ACTCTG
 1001 GTATGAAAAG GATGGCTGGT ACTACACAGC GAACTACTTC TTA⁻AAATAAA
 1051 AAGTCCCGGT TTGAGCTGGG CTTTTTATTT TGAAAGTGAC TAACAAAAAA
 1101 TGTAATAAAA ATGTAATAAT CCAAGTAAGT TGTATAAAAT TTGCAGAATT
 1151 AGAACGTTTT ATTGATAAAT ACACCTTATG AAGAGTATTT TTGGCTATAT
 1201 TTGCGCATT⁻A TAGGGTTGAA TGTAACACTA TATGTAGAAT TC

FIGURE 6




FIGURE 7

MetAlaLeuThrGluAlaTrpLeuIleGluLysAlaAsnArgLysLeuAsnThrSerGly
 ATGGCATTAAACAGAGGCATGGCTAATTGAAAAAGCAAATCGCAAATTGAATACGTCAGGT
 186 -----+-----+-----+-----+-----+-----+-----+----- 245
 TACCGTAATTGTCTCCGTACCGATTAACCTTTTCGTTTAGCGTTTAACCTATGCAGTCCA

 MetAsnLysAlaThrSerAspLysThrArgAsnValIleLysLysMetAlaLysGluGly
 ATGAATAAAGCTACATCTGATAAGACTCGGAATGTAATTAATAAATGGCAAAGAAGGG
 246 -----+-----+-----+-----+-----+-----+-----+----- 305
 TACTTATTTGATGTAGACTATTCTGAGCCTTACATTAATTTTTTACCGTTTTCTTCCC

 IleTyrLeuCysValAlaGlnGlyTyrArgSerThrAlaGluGlnAsnAlaLeuTyrAla
 ATTTATCTTTGTGTGCGCAAGGTTACCGCTCAACAGCGGAACAAATGCGCTATATGCA
 306 -----+-----+-----+-----+-----+-----+-----+----- 365
 TAAATAGAAACACAACGCGTTCCAATGGCGAGTTGTGCGCTTGTTTTACGCGATATACGT

 GlnGlyArgThrLysProGlyAlaIleValThrAsnAlaLysGlyGlyGlnSerAsnHis
 CAAGGGAGAACCAACCTGGAGCGATTGTACTAATGCTAAAGGTGGCAATCTAATCAT
 366 -----+-----+-----+-----+-----+-----+-----+----- 425
 GTTCCCTCTTGGTTTGGACCTCGCTAACAATGATTACGATTTCCACCGTTAGATTAGTA

 AsnPheGlyValAlaValAspLeuCysLeuTyrThrSerAspGlyLysAspValIleTrp
 AATTTCCGTGTAGCAGTTGATTTGTGCTTGATACGAGCGACGGAAGATGTTATTTGG
 426 -----+-----+-----+-----+-----+-----+-----+----- 485
 TTAAAGCCACATCGTCAACTAAACACGAACATATGCTCGCTGCCTTTTCTACAATAAACC

 GluSerThrThrSerArgTrpLysLysValValAlaAlaMetLysAlaGluGlyPheGlu
 GAGTCGACAACTTCCCGGTGGAAAAAGGTTGTTGCTGCTATGAAAGCGGAAGGATTCGAA
 486 -----+-----+-----+-----+-----+-----+-----+----- 545
 CTCAGCTGTTGAAGGGCCACCTTTTCCAACAACGACGATACTTTCGCTTCTCTAAGCTT

 TrpGlyGlyAspTrpLysSerPheLysAspTyrProHisPheGluLeuCysAspAlaVal
 TGGGGCGGAGATTGAAAAAGTTTTAAAGACTATCCGCATTTTGAAGTATGTGACGCTGTA
 546 -----+-----+-----+-----+-----+-----+-----+----- 605
 ACCCGCCTCTAACCTTTTCAAAATTTCTGATAGGCGTAAACTTGATACACTGCGACAT

 SerGlyGluLysIleProThrAlaThrGlnAsnIhrAsnProAsnArgHisAspGlyLys
 AGTGGTGAGAAAATCCCTACTGCGACACAAAACACCAATCCAAACAGACATGATGGGAAA
 606 -----+-----+-----+-----+-----+-----+-----+----- 665
 TCACCACTCTTTAGGGATGACGCTGTGTTTTGTGGTTAGGTTTGTCTGTACTACCTTT

 IleValAspSerAlaProLeuLeuProLysMetAspPheLysSerAsnProAlaArgMet
 ATCGTTGACAGCGCGCCACTATTGCCAAAAATGGACTTTAAATCAAATCCAGCGCGCATG
 666 -----+-----+-----+-----+-----+-----+-----+----- 725
 TAGCAACTGTCGCGCGGTGATAACGGTTTTTACCTGAAATTTAGTTTAGGTCGCGCGTAC

 TyrLysSerGlyThrGluPheLeuValTyrGluHisAsnGlnTyrTrpTyrLysThrTyr
 TATAAATCAGGAAGTGTGTTCTTGTATATGAACATAATCAATATTGGTACAAGACGTAC
 726 -----+-----+-----+-----+-----+-----+-----+----- 785
 ATATTTAGTCCTTGACTCAAGAATCATATACTTGTATTAGTTATAACCATGTTCTGCATG

FIGURE 8 (START)

	IleAsnAspLysLeuTyrTyrMetTyrLysSerPheCysAspValValAlaLysLysAsp	
	ATCAACGACAAATTATACTACATGTATAAGAGCTTTTGGCATGTTGTAGCTAAAAAAGAT	
786	-----+-----+-----+-----+-----+-----+-----	845
	TAGTTGCTGTTTAATATGATGTACATATTCTCGAAAACGCTACAACATCGATTTTTTCTA	
	AlaLysGlyArgIleLysValArgIleLysSerAlaLysAspLeuArgIleProValTrp	
	GCAAAAGGACGCATCAAAGTTTGAATTAAAAGCGCGAAAGACTTACGAATTCAGTTTGG	
846	-----+-----+-----+-----+-----+-----+-----	905
	CGTTTTCTGCGTAGTTTCAAGCTTAATTTTCGCGCTTTCTGAATGCTTAAGGTCAAACC	
	AsnAsnThrLysLeuAsnSerGlyLysIleLysTrpTyrAlaProAsnThrLysLeuAla	
	AATAACACAAAATTGAATTCTGGGAAAATTAAATGGTATGCACCCAATACAAAATTAGCA	
906	-----+-----+-----+-----+-----+-----+-----	965
	TTATTGTGTTTTAACTTAAGACCCTTTTAATTTACCATACGTGGGTATGTTTTAATCGT	
	TrpTyrAsnAsnGlyLysGlyTyrLeuGluLeuTrpTyrGluLysAspGlyTrpTyrTyr	
	TGGTACAACAACGAAAAGGATACTTGGAACCTCTGGTATGAAAAGGATGGCCTGGTACTAC	
966	-----+-----+-----+-----+-----+-----+-----	1025
	ACCATGTTGTTGCCTTTTCCTATGAACCTTGAGACCATACTTTTCCTACCGACCATGATG	
	ThrAlaAsnTyrPheLeuLys	
	ACAGCGAACTACTTCTTAAAA	
1026	-----+-----+-----+-----+-----+-----+-----	1046
	TGTCGCTTGATGAAGAATTTT	




FIGURE 9




FIGURE 10

1. The first part of the document discusses the importance of maintaining accurate records of all transactions and the role of the accounting department in ensuring the integrity of the financial statements. It also highlights the need for transparency and accountability in the reporting process.

2. The second part of the document focuses on the implementation of internal controls to prevent fraud and ensure the accuracy of the financial data. It outlines the key components of a robust internal control system, including segregation of duties, authorization procedures, and regular monitoring and review.

3. The third part of the document addresses the challenges faced by the accounting department in managing complex financial transactions and the importance of staying up-to-date with the latest accounting standards and regulations. It also discusses the role of technology in streamlining the accounting process and improving efficiency.

4. The fourth part of the document provides a detailed overview of the accounting cycle, from the initial recording of transactions to the final preparation of the financial statements. It includes a step-by-step guide to each stage of the cycle, along with examples and practical tips for ensuring accuracy and compliance.

5. The fifth part of the document discusses the importance of communication and collaboration between the accounting department and other departments within the organization. It emphasizes the need for clear lines of communication and regular reporting to ensure that all stakeholders are informed and aligned with the financial goals of the organization.

6. The sixth part of the document provides a summary of the key findings and recommendations of the study. It highlights the areas where the accounting department can improve its performance and the steps that should be taken to address any identified weaknesses or gaps in the current system.

7. The seventh part of the document includes a list of references and a bibliography, providing a comprehensive overview of the sources used in the research. It also includes a list of appendices, which contain additional information and data that support the findings of the study.

8. The eighth part of the document is a conclusion, summarizing the overall findings of the study and providing a final statement on the importance of the accounting department in ensuring the financial health and success of the organization.

9. The ninth part of the document is a list of figures and tables, providing a visual representation of the data and results of the study. It includes a list of figures, which are graphs and charts, and a list of tables, which are data tables.

10. The tenth part of the document is a list of figures and tables, providing a visual representation of the data and results of the study. It includes a list of figures, which are graphs and charts, and a list of tables, which are data tables.




Fig. 1




FIGURE 2




FIGURE 3




Fig. 4




FIGURE 5

1 AAGCTTTACT GGATAACGAC AAAC TAGAAC TGACAGATGA AGGACTGAAA
 51 GGCCTTGACG AACAGCTAGG AGCATTGCAA GAAACCGATG CTTATTTGTT
 101 TGCTCAAGAA AGCGAGGCGG GCGGGAAC TGTTATTIGA ACAATTTACT
 151 AATCGAGCTA AAAAATATCG AAAGGATGAT TAATAATGGC ATTAACAGAG
 201 GCA1GGCTAA TTGAAAAAGC AAATCGCAAA TTGAATACCT CAGGTATGAA
 251 TAAAGCTACA TCTGATAADA CTGGGAATGT AATTAAAAAA ATGGCAAAAG
 301 AAGGGATTTA TCTTCTGTT GCGCAAGGTT ACCGETCAAC AGCGGAACAA
 351 AATGGCTAT ATGCACAAGG GAGAACCAAA CCTCGAGCGA TTGTTACTAA
 401 TGCTAAAGG1 GGGCAATCTA ATCA1AATT1 CGGTGTAGCA GTTGATTTGT
 451 GCTTGTATAC GAGCGACGG1 AAAGATGTA TTTGGGAGTC GACAAC1100
 501 CGGTGGAAAA AGGT1GTTC TCTA1GAAA GCGGAAGGAT TCGA1GGGG
 551 CGGAGATTGG AAAAGT1TTA AAGACTATCC GCA1TTTGAA CTA1GT1GAGG
 601 CTGTAACTGG TGAGAAAATC C1ACTGCGA CACAAAACAC GAATCCAAAC
 651 AGACATGATG GGAAAATCG1 TGAGAGCGCG CCACTATTGC CAAAATGGA
 701 CTT1AAATCA AATCCAGCGC GCATG1ATAA ATCAGGAAC1 GAGTTC1TAG
 751 TATATGAACA TAATCAATAT TGG1ACAAGA CGTACATCAA CGACAAATTA
 801 TACTACATGT ATAAGAGC11 TTCCGATGTT GTAGCTAAAA AAGATGCAAA
 851 AGGACGGATC AAAGTTGAA 13AAAAGCGC GAAAGACTTA CDAATTCAG
 901 TTTGGAA1AA CACAAAATTG AATTC1GGGA AAATTAATG GTATGCACCG
 951 AATACAAAAT TAGCATGGTA CAACAACGGA AAAGGATAGT TCGAAC1CTG
 1001 GTATGAAAAG GATGGCTGGT ACTACACAGC GAAC1ACTTC TTAATAATAA
 1051 AAGTCCCGGT TTGAGC1GGG CTTTTATTT TCAAAG1GAG TAA1AAAAA
 1101 TGTAATAAAA ATG1AATAAT CCAAGTAAGT TGTATAAAAT TTCCAGAATT
 1151 AGAACGTTT1 ATTGATAAAT AGACCT1ATG AAGAGTATTT T1GGCTATAT
 1201 TTGCGCATT1 TAGGGTTGAA TGTAACACTA TATGTAGAAT TC

FIGURE 6




FIGURE 7

MetAlaLeuThrGluAlaTrpLeuIleGluLysAlaAsnArgLysLeuAsnThrSerGly
 186 ATGGCATTAAACAGAGGCATGCCCTAATTGAAAAAGCAAATCGCAATTTGAATACGTCAGGT 245
 TACCGTAATTGTCTCCGTACCGATTAACTTTTTCGTTTACGCTTTAACTTATGCAGTCCA

 MetAsnLysAlaThrSerAspLysThrArgAsnValIleLysLysMetAlaLysGluGly
 246 ATGAAATAAAGCTACATCTGATAAGACTCGGAATGTAAATAAAAAATGGCAAAAGAAAGGG 305
 TACTTATTTGGATGTAGACTATTCIGAGGCCAATTAATTTTACCGTTTCTTCCG

 IleTyrLeuCysValAlaGlnGlyTyrArgSerIleAlaGluGlnAsnAlaLeuTyrAla
 306 ATTTATCTTTGTGTTGGCAAGGTTACCGCTCAACACCGGAACAAAAATGGCCTATATGCA 365
 TAAATAGAAACACAACCGCTTCCAATGGCGAGTTGTCCGCTTGTITACCGCAATACGT

 GlnGlyArgThrLysProGlyAlaIleValThrAsnAlaLysGlyGlyGlnSerAsnHis
 366 CAAGGGAGAACCACCAACCTGGAGCGATTGTTACTAATGCTAAAGGAGGCAATCTAATCAT 425
 GTTCCCTCTTGGTGGACCTCGCTAACAATGATTACGATTTCCACCCGTTAGATTAGTA

 AsnPheGlyValAlaValAspLeuGlyLeuIleThrSerAspGlyLysAspValIleIle
 426 AATTTCCGTTGTAGCAGTTGATTTGTGCTTGTATACGAGCGACGCAAAAGATGTTATTTGG 485
 TTAAGGCCACATCGTCAACTAAACACGAACATATGCTCGCTGCTTTCCTACCAATAAAGC

 GluSerThrThrSerArgIleLysLysValValAlaAlaMetLysAlaGluGlyPheGlu
 486 GATTCGACAACTTCCCGGTGGAAAAAGGTTGTTGCTGCTATGAAAGCGGAAGGATTCGAA 545
 CTCACCTGTTGAAGGGCCACCTTTTCCAACAACGAGGATACTTCCGCTTCTTAAGCTT

 TrpGlyGlyAspIleLysSerPheLysAspIleProHisPheGluLeuCysAspAlaVal
 546 TCGGCGCGAGATGGAAAAAGTTTAAAGACTATCGGCAATTTGAACATAAGTACCTGTA 605
 ACCCGGCTCTAACCTTTCAAAAATTTCTGATAGGCGTAACCTGATACACTGCGACA

 SerGlyGluLysIleProIleAlaIleGlnAsnIleAsnProAsnArgHisAspGlyLys
 606 AGTGGTGAGAAAAATCCCTACTGGGACACAAAACACCAATCCAAACAGACATGATCGGAAA 665
 TCACCAGTCTTTTAGGCATGACCGCTGIGITTTGGGTTAGGTTTGTCTGTACTACCTTT

 IleValAspSerAlaProLeuLeuProLysMetLysPheLysSerAsnProAlaArgMet
 666 ATCGTTGACACCGCGCCACTATTGCCAAAAATGGACTTAAATCAAAATCCAGCGCGGATG 725
 TAGCAACTGTCGCGCGGTGATAACGGTTTTTACCTGAATTTAGTAAAGCTCCGCGTAC

 TyrLysSerGlyThrGluPheLeuValTyrGluHisAsnGlnTyrTrpTyrLysThrTyr
 726 TATAAATCAGGAAGTGAATCTTAGTAAATGAACATAATCAATATCGGTACAAGACGTAC 785
 ATATTTAGTCTTGACTCAGAAATCATATCTTGTATAGTAAATACCAATGTTCTGATG

FIGURE 8 (START)

[illegible]




FIGURE 9




FIGURE 10

